Clinical Trial Update: Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC [Phase 4]

View source ↗

Summary

Trial update for anlotinib plus pemetrexed versus pemetrexed for previously untreated elderly or PS 2 non-squamous NSCLC (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Advanced Non-squamous NSCLC | Phase 4 | Status: UNKNOWN